John West, MD
Family Medicine · Mc Cook, NENPI 1063485290
Payments from drug & device makers
Across 118 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$461
- AstraZeneca$419
- Johnson & Johnson$194
- AbbVie$158
- Boehringer Ingelheim$143
- Novartis$70
- plus $432 from 15 others
What the payments were for
- Food & beverage$1,81697%
- Education$111%
- Other$513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $461 |
| AstraZeneca | 5 | $419 |
| Johnson & Johnson | 18 | $194 |
| AbbVie | 13 | $158 |
| Boehringer Ingelheim | 11 | $143 |
| Novartis | 5 | $70 |
| Lilly USA, LLC | 5 | $68 |
| Boston Scientific | 2 | $55 |
| Pfizer | 3 | $48 |
| Merck | 3 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Baxter Healthcare | 1 | $25 |
| Welch Allyn | 1 | $25 |
| Organon | 2 | $21 |
| Electromed, Inc. | 2 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$392
- SYMBICORT$257
- BYDUREON$136
- BREZTRI$135
- BEVESPI AEROSPHERE$135
How this compares
$1,878 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $76,852 |
| OzempicSemaglutide | 60 | $65,326 |
| XifaxanRifaximin | 13 | $44,714 |
| JardianceEmpagliflozin | 63 | $32,660 |
| TrulicityDulaglutide | 32 | $29,776 |
| FarxigaDapagliflozin Propanediol | 49 | $26,626 |
| JanuviaSitagliptin Phosphate | 70 | $22,738 |
| XareltoRivaroxaban | 41 | $20,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $20,116 |
| RybelsusSemaglutide | 20 | $17,604 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,293 |
| LinzessLinaclotide | 14 | $6,951 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,446 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $4,640 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $4,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $461 | $82,93180 claims |
| PfizerEliquis | $48 | $76,852149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $419 | $46,74181 claims |
| Boehringer IngelheimJardiance | $143 | $32,66063 claims |
| Lilly USA, LLCTrulicity, Humalog | $68 | $31,73146 claims |
| MerckJanuvia, Janumet Xr | $35 | $29,18482 claims |
| Johnson & JohnsonXarelto | $194 | $20,42041 claims |
| AbbVieLinzess | $158 | $6,95114 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $3,86817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Mc Cook
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.